Mark Jeffrey DeLong - 15 Jun 2021 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Senior Vice President
Signature
/s/ David Watson, attorney-in-fact for Mark Delong
Issuer symbol
APLS
Transactions as of
15 Jun 2021
Net transactions value
-$197,750
Form type
4
Filing time
16 Jun 2021, 16:32:12 UTC
Previous filing
19 May 2021
Next filing
16 Jul 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $62,080 +4,000 +42% $15.52 13,490 15 Jun 2021 Direct
transaction APLS Common Stock Sale $259,830 -4,000 -30% $64.96 9,490 15 Jun 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -4,000 -8.3% $0.000000 44,000 15 Jun 2021 Common Stock 4,000 $15.52 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant date, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.